Avacta Group interim results & investor presentation on 28th September

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its unaudited interim results for the 6 months ended 30 June 2020 on Monday, 28 September 2020.

Shareholder webinar

A shareholder and investor webinar presentation by Alastair Smith, Chief Executive Officer, Tony Gardiner, Chief Financial Officer and Neil Bell, Chief Development Officer will take place at 10:30 hrs on Monday, 28 September 2020.

The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform.

Avacta is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base so that its strategy, business model and performance are clearly understood.

Investors can sign up to Investor Meet Company for free and then click “Add to meet” Avacta Group via the following link to join the webinar:

https://www.investormeetcompany.com/avacta-group-plc/register-investor

Investors who have already registered and clicked “Add to meet” Avacta Group plc, will be automatically invited.

·      Investors are encouraged to submit questions pre-event via the Investor Meet Company Platform, once registered.

·      Questions can be submitted pre-event via the “Ask a Question” function located on your Investor Meet Company dashboard, in addition questions can be submitted during the live event.

·      Whilst the Company will not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications.

·      Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

·      Investor feedback can also be submitted post the event on the Investor Meet Company platform to ensure the Company can understand the views of all elements of its shareholder base.

Analyst briefing

A sell-side analyst briefing given by Alastair Smith, Chief Executive Officer, Tony Gardiner, Chief Financial Officer and Neil Bell, Chief Development Officer, will be held by webcast presentation, followed by a Q&A session, at 09.00 hrs on Monday, 28 September 2020.

Pre-registration is required for attendance to the call. To confirm attendance, please email avacta@yellowjerseypr.com and you will be sent the link to join.

The presentation will be posted on the Company’s website at the following address:

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is